The content of this website is intended for healthcare professionals only

TB drug resistance is growing around the world

Major study shows TB resistant to both first and second-line drugs

Mark Gould

Thursday, 30 August 2012

A large international study reveals “alarming” levels of tuberculosis that are resistant to both first-line and second-line drugs.

The study published online in The Lancet today reveals high levels of resistance to at least one second-line drug (43.7%) among multi-drug-resistant (MDR) TB patients from eight countries in Africa, Asia, Europe, and Latin America. Worse still, the study found higher than expected overall levels of extensively drug-resistant (XDR) TB.

Tracy Dalton, the study’s lead author from the US Centers for Disease Control and Prevention (CDC) and colleagues, used population-based data to quantify the extent of XDR TB and identify risk factors for being infected with a strain resistant to second-line drugs among people with MDR TB from Estonia, Latvia, Peru, the Philippines, Russia, South Africa, South Korea, and Thailand.

Isolates from 1278 adults with MDR TB were shipped to the US CDC and tested for susceptibility to 11 first-line and second-line anti-tuberculosis drugs.

The prevalence of resistance varied widely between countries. Overall, resistance to any second-line drug was detected in nearly 44% of patients, ranging from 33% in Thailand to 62% in Latvia. In a fifth of cases, resistance to at least one second-line injectable drug was identified, ranging from 2% in the Philippines to 47% in Latvia. The proportion of cases with resistance to a fluoroquinolone was almost 13%, with the lowest prevalence in the Philippines (7%) and the highest in South Korea (32%).

XDR TB was detected in 6.7% patients overall, with prevalence in South Korea (15.2%) and Russia (11.3%) more than twice the WHO global estimates for the same time period of 5.4%.

According to Dalton, “our country-specific results can be extrapolated to guide in-country policy for laboratory capacity and for designing effective treatment recommendations for MDR TB.”

“Drug-resistant TB is more difficult and costly to treat, and more often fatal. Internationally, it is particularly worrisome in areas with fewer resources and less access to effective therapies. As more individuals are diagnosed with, and treated for, drug-resistant TB, more resistance to second-line drugs is expected to emerge.” So far, XDR TB has been reported in 77 countries worldwide, Dr Dalton added, but she stressed the exact prevalence remains unclear.

Among the study’ s other key findings were that risk of XDR disease was more than quadrupled in previously treated patients, and previous treatment with second-line drugs was consistently the strongest risk factor for resistance to these drugs.

Further analysis also found unemployment, a history of imprisonment, alcohol abuse, and smoking as factors associated with resistance to second-line injectable drugs, suggesting that  “social factors should be taken into account in the management of TB”, says Dalton.

“Most international recommendations for TB control have been developed for MDR TB prevalence of up to around 5%. Yet now we face prevalence up to ten times higher in some places, where almost half of the patients with infectious disease are transmitting MDR strains”, warns Sven Hoffner from the Swedish Institute for Communicable Disease Control in a linked comment.

And Hoffner adds: “These results show that XDR TB is increasingly a cause for concern, especially in areas where prevalence of MDR TB is high. Nevertheless, information remains insufficient to give a clear view of the worldwide distribution and true magnitude of XDR TB. Updated information on MDR TB and investigation of the trends are urgently needed...especially since the true scale of the burden of MDR and XDR tuberculosis might be underestimated and seem to be rapidly increasing.”

Registered in England and Wales. Reg No. 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Reg No. 30158470